Free Content Effects of grapefruit juice on the absorption of levothyroxine

Authors: Lilja, Jari J.; Laitinen, Kalevi1; Neuvonen, Pertti J.2

Source: British Journal of Clinical Pharmacology, Volume 60, Number 3, September 2005 , pp. 337-341(5)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Aims

Our aim was to study the effect of grapefruit juice on the pharmacokinetics of levothyroxine. Methods

In a randomized cross-over study with two phases, 10 healthy subjects ingested 200 ml grapefruit juice or water (control) three times daily for 2 days. On day 3, a single 600 µg dose of levothyroxine was administered with 200 ml grapefruit juice or water, which was also ingested 1 h before and 1 h after levothyroxine. Serum concentrations of total thyroxine (T4) and thyroid-stimulating hormone (TSH) were measured up to 24 h. Results

Grapefruit juice decreased slightly (11%; P < 0.01) the maximal increase of T4 concentration after ingestion of levothyroxine from 66.4 nmol l-1 to 59.4 nmol l-1 (95% CI on the difference -11.3, -2.7). The incremental areas under the serum T4 concentration-time curve (dAUC) during the first 4 and 6 h were also decreased slightly: dAUC(0,4 h) by 13% (P < 0.05), from 195 nmol l-1 h to 169 nmol l-1 h (95% CI -51, -1) and dAUC(0,6 h) by 9% (P = 0.085), from 298 nmol l-1 h to 271 nmol l-1 h (95% CI -58, 4). The decrease in the serum concentration of TSH (1.25 mU l-1) measured 24 h after ingestion of levothyroxine, was not altered by grapefruit juice. Conclusions

Grapefruit juice may slightly delay the absorption of levothyroxine, but it seems to have only a minor effect on its bioavailability. Accordingly, the clinical relevance of the grapefruit juice-levothyroxine interaction is likely to be small.

Keywords: food-drug interaction; grapefruit juice; levothyroxine

Document Type: Research article

DOI: 10.1111/j.1365-2125.2005.02433.x

Affiliations: 1: Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland 2: Department of Clinical Pharmacology

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A